Status:
WITHDRAWN
Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer
Lead Sponsor:
AbbVie
Conditions:
Exocrine Pancreatic Insufficiency (EPI)
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Exocrine pancreatic insufficiency (EPI) is a condition where the pancreas does not have enough pancreatic enzymes to break down food. Some symptoms of EPI are frequent gas/bloating, unexplained stomac...
Eligibility Criteria
Inclusion
- Diagnosis of exocrine pancreatic insufficiency (EPI).
- Participants who are on pancreatic enzyme replacement therapy (PERT) at the time of consent must have a clinical diagnosis of EPI by their physician.
Exclusion
- History of cystic fibrosis, chronic pancreatitis, pancreatectomy, pancreatic cancer, or fibrosing colonopathy.
Key Trial Info
Start Date :
May 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04315311
Start Date
May 6 2020
End Date
September 22 2021
Last Update
November 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.